GSK (GSK) has agreed to acquire Boston Pharmaceuticals' investigational steatotic liver disease treatment efimosfermin alfa for up to $2 billion in cash, the companies said Wednesday.
The company will pay $1.2 billion upfront, with potential for certain additional milestone payments amounting to $800 million. Under the terms of the deal, GSK will buy Boston Pharmaceuticals unit BP Asset IX to access efimosfermin.
GSK will be responsible for success-based milestone payments, as well as tiered royalties for efimosfermin owed to Novartis Pharma, the companies said.
GSK shares were up 2.1% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.